SS-31 vs MOTS-c at a glance
| Property | SS-31 (elamipretide) | MOTS-c |
|---|---|---|
| Structure | Synthetic tetrapeptide, D-Arg-Dmt-Lys-Phe-NH2 | 16-amino-acid peptide encoded in mitochondrial DNA |
| Origin | Spun out of opioid receptor peptide work by Hazel Szeto and Peter Schiller, early 2000s | Found inside the mitochondrial 12S rRNA gene by the Lee/Cohen lab, USC, 2015 |
| Primary mechanism studied | Binds cardiolipin in the inner mitochondrial membrane | Disrupts folate-dependent metabolism to activate AMPK |
| Research focus | Cardiolipin-linked mitochondrial disease, heart failure | Insulin sensitivity, exercise physiology, metabolic aging |
| Strongest human data | 96.1-meter six-minute-walk gain in an 8-patient open-label extension | None interventional; largest study is a 104-man observational cohort |
| Approved drug product | Forzinity (elamipretide hydrochloride), FDA accelerated approval, September 2025, Barth syndrome only | None |
| 2026 regulatory development | Already approved; label expansion work ongoing | FDA advisory committee voted, non-bindingly, to recommend it for compounding |
A cardiolipin-binding drug against a genome-encoded microprotein
SS-31 started as a byproduct of opioid receptor research. Hazel Szeto and Peter Schiller were studying peptides that activate opioid receptors when they noticed one of their compounds, built from alternating aromatic and cationic amino acids, concentrated itself inside mitochondria rather than acting where they expected. That accidental finding became SS-31, later renamed elamipretide as it moved toward drug development, and sold for years under the earlier name Bendavia.
MOTS-c has a stranger origin story. Mitochondria carry a small genome of their own, long assumed to code only for the standard respiratory-chain proteins. In 2015, Changhan Lee, Pinchas Cohen, and colleagues at the University of Southern California found a 16-amino-acid open reading frame hidden inside the gene for the mitochondrial 12S rRNA subunit and named the peptide it produces MOTS-c (Lee et al., Cell Metabolism 21(3):443-454, 2015). Nobody engineered MOTS-c. The body was already making it, and researchers just had not noticed.
One compound was built for a purpose and found a target it was not designed for. The other was found first and had to be explained afterward. That difference in origin tracks through everything else about how the two peptides have been studied since.
What the mechanism research shows for SS-31
Zhao and colleagues, working with Szeto and Schiller, laid out the core mechanism in a 2004 Journal of Biological Chemistry paper: the peptide inhibited mitochondrial swelling, blocked oxidative cell death, and reduced reperfusion injury in isolated mitochondria and cell culture, all traceable to one binding event (Zhao et al., J Biol Chem 279(33):34682-90, 2004). SS-31 attaches to cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane, and reported uptake runs from 1,000-fold to 5,000-fold relative to the surrounding cytosol.
That binding mode sets SS-31 apart from older mitochondria-targeted compounds such as MitoQ, which ride the organelle's own electrical potential to accumulate. A damaged or partially depolarized mitochondrion loses most of that potential and stops concentrating a TPP+-based compound. SS-31 does not depend on the potential at all, so it keeps working in the mitochondria that need help most.
What the mechanism research shows for MOTS-c
MOTS-c's pathway runs through one-carbon metabolism rather than membrane binding. Lee's 2015 paper found the peptide disrupts folate-dependent carbon metabolism, which limits purine synthesis, raises intracellular AMP, and activates AMP-activated protein kinase, the cell's main energy-sensing switch. In mice on a high-fat diet, five days of MOTS-c injections improved insulin sensitivity and blunted weight gain; the effect disappeared in AMPK-knockout mice, confirming the pathway did the work.
A 2018 follow-up from the same lab found MOTS-c also moves into the nucleus under metabolic stress, where it drives expression of NRF2-regulated antioxidant genes (Kim, Son, Benayoun, Lee, Cell Metabolism, 2018). Reynolds and colleagues later measured the peptide directly in exercising humans: skeletal muscle MOTS-c rose roughly 12-fold after a single bout of exercise, plasma levels rose about 1.5-fold, and aged mice given the peptide three times a week gained measurable grip strength and endurance versus untreated controls (Reynolds et al., Nature Communications 12:470, 2021).
Neither mechanism touches the other peptide's target. SS-31 stabilizes a membrane lipid; MOTS-c reprograms a metabolic pathway and, in some conditions, gene transcription. Comparing them by potency or dose makes little sense. They are not competing for the same job.
Human trial evidence: an approved drug against a trial that has not reported
SS-31 has been through randomized human trials with mixed results. The PROGRESS-HF trial gave 71 heart failure patients with reduced ejection fraction either placebo or one of two elamipretide doses for 28 days and found no significant change in the primary endpoint, left ventricular end-systolic volume (Butler et al., J Card Fail 26(5):429-437, 2020). The TAZPOWER trial in Barth syndrome, a genetic cardiolipin disorder, told a more complicated story: the randomized, placebo-controlled crossover phase missed its co-primary endpoints at 12 weeks, but an open-label extension without a placebo arm later showed the 8 patients who completed it gained 96.1 meters on the six-minute walk test and improved knee extensor strength by more than 45 percent by week 168.
MOTS-c has no comparable data because it has no completed interventional human trial of any kind. NCT04027712, registered on ClinicalTrials.gov, tracks naturally occurring MOTS-c levels against platelet reactivity and mortality in diabetic patients with coronary artery disease; it does not administer the peptide to anyone. A genuine interventional trial exists now: a Phase 2a study sponsored by Hudson Biotech began recruiting 120 adults with prediabetes and overweight in February 2026, testing 12 weeks of subcutaneous MOTS-c against placebo with insulin sensitivity, measured by the Matsuda index, as the primary endpoint (ClinicalTrials.gov NCT07505745). Results are not expected before 2028. A 2023 review in Frontiers in Endocrinology summarized the state of the field bluntly: no effective method of applying MOTS-c in the clinic has been developed (Zheng, Wei, Wang, Front Endocrinol 14:1120533, 2023).
Regulatory paths that split in opposite directions
The clearest way to see how far apart these two peptides sit is to watch what happened to each of them with the FDA within the same twelve months. On September 19, 2025, the FDA granted accelerated approval to elamipretide hydrochloride, marketed as Forzinity, for Barth syndrome in patients weighing at least 30 kg. It is the first approved treatment for that disease and the first approved therapy for any primary mitochondrial disease, carrying Orphan Drug, Fast Track, Priority Review, and Rare Pediatric Disease designations. The approval does not extend to heart failure or any other condition SS-31 has been studied for, and it does not apply to SS-31 sold outside a prescription context.
MOTS-c's 2026 regulatory moment looked nothing like a drug approval. On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee met to evaluate seven peptides, MOTS-c among them, for inclusion on the Section 503A Bulks List, the list that determines which raw substances licensed compounding pharmacies may legally prepare into patient prescriptions. FDA's own staff recommended against adding MOTS-c, citing no effective clinical protocol and a single ongoing prediabetes trial with no results yet reported. The committee voted anyway, 7-5 with two abstentions, to recommend MOTS-c for inclusion (NCPA newsroom, July 31, 2026).
That vote is a recommendation, not a decision. The Secretary of Health and Human Services still has to approve adding MOTS-c to the Bulks List through formal rulemaking, a process not expected to conclude before 2027, and pharmacies cannot legally compound it until that happens. A compounding listing would also do something an FDA drug approval does not: it says nothing about whether MOTS-c is safe or effective for any specific use, only that a licensed pharmacy may prepare it as an ingredient. Reading the two peptides' 2026 regulatory status side by side, one is a prescription drug dispensed under medical supervision for one rare disease; the other is, at best, on a path toward becoming a compounding-pharmacy ingredient with no approved indication attached to it at all.
Storage and research handling in Indonesia
Neither compound has an approved research-grade formulation sold outside specialty channels, and both ship to laboratories as lyophilized powder that follows the same basic handling rules as other short synthetic peptides. Reconstitution with bacteriostatic water, gentle mixing, and prompt refrigeration all reduce degradation risk, covered in general terms in the reconstitution guide on this site.
Ambient humidity above 70 percent, common across Bali and Java for much of the year, accelerates degradation of an opened lyophilized vial faster than the temperate conditions most published stability data was collected under. The lyophilized peptide storage guide covers the two-tier cold-chain setup that tropical labs typically need. Once a reconstitution concentration is set for either peptide, the dosing calculator works out the volume and draw math for a given vial. Full single-compound detail is available in the SS-31 research overview and the MOTS-c research overview; MOTS-c is also listed in the mitochondrial peptide category. Readers comparing MOTS-c against a different longevity peptide may also find the Epitalon vs MOTS-c comparison useful.